Renaissance Capital logo

Corvus prices IPO at $15, the low end of the range

March 22, 2016
CRVS

Corvus Pharmaceuticals, which is developing checkpoint inhibitors to treat solid tumors, raised $71 million by offering 4.7 million shares at $15, the low end of the range of $15 to $17. Corvus Pharmaceuticals plans to list on the Nasdaq under the symbol CRVS. Credit Suisse and Cowen & Company acted as lead managers on the deal.